Myocyte hypertrophy in the transplanted heart: A morphometric analysis

M. Imakita, H. D. Tazelaar, R. A. Rowan, M. A. Masek, M. E. Billingham

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

In order to better define long-term changes in the transplanted heart with respect to the effects of cyclosporine and the ischemic time of the donor heart, endomyocardial biopsies were examined ultrastructurally from 20 cardiac transplant recipients three years posttransplantation. The biopsies were divided into four groups of five based on the donor heart ischemic time in 'on-site' versus 'distantly procured' hearts and on the immunosuppression protocol: group A: 'on site' donor hearts and cyclosporine-based immunosuppression; group B: 'on site' donor hearts with conventional immunosuppression (azathioprine-based immunosuppression without cyclosporine): group C: distantly procured donor hearts treated with cyclosporine; and group D: distantly procured donor hearts treated with conventional immunosuppression. All four groups showed a significant increase in the average width of myocytes when compared with normal myocardium, (group A, P < 0.05; groups B, C, D, P < 0.01). Also, there was a significant difference between the average widths of myocytes from on-site donor hearts and distantly procured donor hearts (P < 0.04). There was no significant difference between the average myocyte widths of groups treated with cyclosporine and those with conventional immunosuppression. This study shows that despite the hypertension induced by cyclosporine, myocyte hypertrophy at 3 years posttransplantation does not appear to be significantly greater than in patients treated with conventional immunosuppression. Distantly procured donor hearts have more hypertrophy. Due to the increasing evidence that cardiac hypertrophy per se may predispose to serious ventricular arrhythmias, this study supports the use of on-site as opposed to distantly procured donor hearts.

Original languageEnglish (US)
Pages (from-to)839-842
Number of pages4
JournalTransplantation
Volume43
Issue number6
StatePublished - 1987
Externally publishedYes

Fingerprint

Muscle Cells
Hypertrophy
Tissue Donors
Immunosuppression
Cyclosporine
Biopsy
Azathioprine
Cardiomegaly
Cardiac Arrhythmias
Myocardium
Hypertension

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

Imakita, M., Tazelaar, H. D., Rowan, R. A., Masek, M. A., & Billingham, M. E. (1987). Myocyte hypertrophy in the transplanted heart: A morphometric analysis. Transplantation, 43(6), 839-842.

Myocyte hypertrophy in the transplanted heart : A morphometric analysis. / Imakita, M.; Tazelaar, H. D.; Rowan, R. A.; Masek, M. A.; Billingham, M. E.

In: Transplantation, Vol. 43, No. 6, 1987, p. 839-842.

Research output: Contribution to journalArticle

Imakita, M, Tazelaar, HD, Rowan, RA, Masek, MA & Billingham, ME 1987, 'Myocyte hypertrophy in the transplanted heart: A morphometric analysis', Transplantation, vol. 43, no. 6, pp. 839-842.
Imakita M, Tazelaar HD, Rowan RA, Masek MA, Billingham ME. Myocyte hypertrophy in the transplanted heart: A morphometric analysis. Transplantation. 1987;43(6):839-842.
Imakita, M. ; Tazelaar, H. D. ; Rowan, R. A. ; Masek, M. A. ; Billingham, M. E. / Myocyte hypertrophy in the transplanted heart : A morphometric analysis. In: Transplantation. 1987 ; Vol. 43, No. 6. pp. 839-842.
@article{9a4094e18e944441b28833ea94e22d4b,
title = "Myocyte hypertrophy in the transplanted heart: A morphometric analysis",
abstract = "In order to better define long-term changes in the transplanted heart with respect to the effects of cyclosporine and the ischemic time of the donor heart, endomyocardial biopsies were examined ultrastructurally from 20 cardiac transplant recipients three years posttransplantation. The biopsies were divided into four groups of five based on the donor heart ischemic time in 'on-site' versus 'distantly procured' hearts and on the immunosuppression protocol: group A: 'on site' donor hearts and cyclosporine-based immunosuppression; group B: 'on site' donor hearts with conventional immunosuppression (azathioprine-based immunosuppression without cyclosporine): group C: distantly procured donor hearts treated with cyclosporine; and group D: distantly procured donor hearts treated with conventional immunosuppression. All four groups showed a significant increase in the average width of myocytes when compared with normal myocardium, (group A, P < 0.05; groups B, C, D, P < 0.01). Also, there was a significant difference between the average widths of myocytes from on-site donor hearts and distantly procured donor hearts (P < 0.04). There was no significant difference between the average myocyte widths of groups treated with cyclosporine and those with conventional immunosuppression. This study shows that despite the hypertension induced by cyclosporine, myocyte hypertrophy at 3 years posttransplantation does not appear to be significantly greater than in patients treated with conventional immunosuppression. Distantly procured donor hearts have more hypertrophy. Due to the increasing evidence that cardiac hypertrophy per se may predispose to serious ventricular arrhythmias, this study supports the use of on-site as opposed to distantly procured donor hearts.",
author = "M. Imakita and Tazelaar, {H. D.} and Rowan, {R. A.} and Masek, {M. A.} and Billingham, {M. E.}",
year = "1987",
language = "English (US)",
volume = "43",
pages = "839--842",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Myocyte hypertrophy in the transplanted heart

T2 - A morphometric analysis

AU - Imakita, M.

AU - Tazelaar, H. D.

AU - Rowan, R. A.

AU - Masek, M. A.

AU - Billingham, M. E.

PY - 1987

Y1 - 1987

N2 - In order to better define long-term changes in the transplanted heart with respect to the effects of cyclosporine and the ischemic time of the donor heart, endomyocardial biopsies were examined ultrastructurally from 20 cardiac transplant recipients three years posttransplantation. The biopsies were divided into four groups of five based on the donor heart ischemic time in 'on-site' versus 'distantly procured' hearts and on the immunosuppression protocol: group A: 'on site' donor hearts and cyclosporine-based immunosuppression; group B: 'on site' donor hearts with conventional immunosuppression (azathioprine-based immunosuppression without cyclosporine): group C: distantly procured donor hearts treated with cyclosporine; and group D: distantly procured donor hearts treated with conventional immunosuppression. All four groups showed a significant increase in the average width of myocytes when compared with normal myocardium, (group A, P < 0.05; groups B, C, D, P < 0.01). Also, there was a significant difference between the average widths of myocytes from on-site donor hearts and distantly procured donor hearts (P < 0.04). There was no significant difference between the average myocyte widths of groups treated with cyclosporine and those with conventional immunosuppression. This study shows that despite the hypertension induced by cyclosporine, myocyte hypertrophy at 3 years posttransplantation does not appear to be significantly greater than in patients treated with conventional immunosuppression. Distantly procured donor hearts have more hypertrophy. Due to the increasing evidence that cardiac hypertrophy per se may predispose to serious ventricular arrhythmias, this study supports the use of on-site as opposed to distantly procured donor hearts.

AB - In order to better define long-term changes in the transplanted heart with respect to the effects of cyclosporine and the ischemic time of the donor heart, endomyocardial biopsies were examined ultrastructurally from 20 cardiac transplant recipients three years posttransplantation. The biopsies were divided into four groups of five based on the donor heart ischemic time in 'on-site' versus 'distantly procured' hearts and on the immunosuppression protocol: group A: 'on site' donor hearts and cyclosporine-based immunosuppression; group B: 'on site' donor hearts with conventional immunosuppression (azathioprine-based immunosuppression without cyclosporine): group C: distantly procured donor hearts treated with cyclosporine; and group D: distantly procured donor hearts treated with conventional immunosuppression. All four groups showed a significant increase in the average width of myocytes when compared with normal myocardium, (group A, P < 0.05; groups B, C, D, P < 0.01). Also, there was a significant difference between the average widths of myocytes from on-site donor hearts and distantly procured donor hearts (P < 0.04). There was no significant difference between the average myocyte widths of groups treated with cyclosporine and those with conventional immunosuppression. This study shows that despite the hypertension induced by cyclosporine, myocyte hypertrophy at 3 years posttransplantation does not appear to be significantly greater than in patients treated with conventional immunosuppression. Distantly procured donor hearts have more hypertrophy. Due to the increasing evidence that cardiac hypertrophy per se may predispose to serious ventricular arrhythmias, this study supports the use of on-site as opposed to distantly procured donor hearts.

UR - http://www.scopus.com/inward/record.url?scp=0023250962&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023250962&partnerID=8YFLogxK

M3 - Article

C2 - 2954283

AN - SCOPUS:0023250962

VL - 43

SP - 839

EP - 842

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 6

ER -